S&P 500   3,895.45 (-0.16%)
DOW   31,574.34 (+0.12%)
QQQ   320.54 (-0.94%)
AAPL   126.16 (-1.28%)
MSFT   234.75 (-0.92%)
FB   264.52 (-0.15%)
GOOGL   2,073.86 (+0.20%)
TSLA   705.04 (-1.86%)
AMZN   3,137.46 (-0.28%)
NVDA   544.71 (-1.62%)
BABA   238.12 (-1.48%)
CGC   35.59 (+2.48%)
GE   13.03 (-0.61%)
MU   92.12 (-2.79%)
NIO   44.10 (-11.37%)
AMD   85.57 (-0.95%)
T   28.36 (+0.96%)
F   12.49 (+4.26%)
ACB   11.40 (+3.26%)
DIS   194.75 (-0.12%)
BA   223.72 (-0.30%)
NFLX   550.38 (-0.05%)
BAC   35.62 (-0.47%)
S&P 500   3,895.45 (-0.16%)
DOW   31,574.34 (+0.12%)
QQQ   320.54 (-0.94%)
AAPL   126.16 (-1.28%)
MSFT   234.75 (-0.92%)
FB   264.52 (-0.15%)
GOOGL   2,073.86 (+0.20%)
TSLA   705.04 (-1.86%)
AMZN   3,137.46 (-0.28%)
NVDA   544.71 (-1.62%)
BABA   238.12 (-1.48%)
CGC   35.59 (+2.48%)
GE   13.03 (-0.61%)
MU   92.12 (-2.79%)
NIO   44.10 (-11.37%)
AMD   85.57 (-0.95%)
T   28.36 (+0.96%)
F   12.49 (+4.26%)
ACB   11.40 (+3.26%)
DIS   194.75 (-0.12%)
BA   223.72 (-0.30%)
NFLX   550.38 (-0.05%)
BAC   35.62 (-0.47%)
S&P 500   3,895.45 (-0.16%)
DOW   31,574.34 (+0.12%)
QQQ   320.54 (-0.94%)
AAPL   126.16 (-1.28%)
MSFT   234.75 (-0.92%)
FB   264.52 (-0.15%)
GOOGL   2,073.86 (+0.20%)
TSLA   705.04 (-1.86%)
AMZN   3,137.46 (-0.28%)
NVDA   544.71 (-1.62%)
BABA   238.12 (-1.48%)
CGC   35.59 (+2.48%)
GE   13.03 (-0.61%)
MU   92.12 (-2.79%)
NIO   44.10 (-11.37%)
AMD   85.57 (-0.95%)
T   28.36 (+0.96%)
F   12.49 (+4.26%)
ACB   11.40 (+3.26%)
DIS   194.75 (-0.12%)
BA   223.72 (-0.30%)
NFLX   550.38 (-0.05%)
BAC   35.62 (-0.47%)
S&P 500   3,895.45 (-0.16%)
DOW   31,574.34 (+0.12%)
QQQ   320.54 (-0.94%)
AAPL   126.16 (-1.28%)
MSFT   234.75 (-0.92%)
FB   264.52 (-0.15%)
GOOGL   2,073.86 (+0.20%)
TSLA   705.04 (-1.86%)
AMZN   3,137.46 (-0.28%)
NVDA   544.71 (-1.62%)
BABA   238.12 (-1.48%)
CGC   35.59 (+2.48%)
GE   13.03 (-0.61%)
MU   92.12 (-2.79%)
NIO   44.10 (-11.37%)
AMD   85.57 (-0.95%)
T   28.36 (+0.96%)
F   12.49 (+4.26%)
ACB   11.40 (+3.26%)
DIS   194.75 (-0.12%)
BA   223.72 (-0.30%)
NFLX   550.38 (-0.05%)
BAC   35.62 (-0.47%)
Log in
NASDAQ:INGN

Inogen Competitors

$50.36
-2.78 (-5.23 %)
(As of 03/2/2021 12:30 PM ET)
Add
Compare
Today's Range
$50.24
Now: $50.36
$52.15
50-Day Range
$43.97
MA: $50.48
$55.99
52-Week Range
$26.57
Now: $50.36
$56.46
Volume2,937 shs
Average Volume167,099 shs
Market Capitalization$1.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.05

Competitors

Inogen (NASDAQ:INGN) Vs. AVNS, EAR, ESTA, SIEN, IVC, and LAKE

Should you be buying INGN stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Inogen, including Avanos Medical (AVNS), Eargo (EAR), Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC), and Lakeland Industries (LAKE).

Inogen (NASDAQ:INGN) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Risk and Volatility

Inogen has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Inogen and Avanos Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inogen03102.25
Avanos Medical12202.20

Inogen currently has a consensus target price of $63.00, indicating a potential upside of 22.35%. Avanos Medical has a consensus target price of $38.40, indicating a potential downside of 15.92%. Given Inogen's stronger consensus rating and higher probable upside, research analysts plainly believe Inogen is more favorable than Avanos Medical.

Institutional & Insider Ownership

95.1% of Inogen shares are owned by institutional investors. Comparatively, 94.8% of Avanos Medical shares are owned by institutional investors. 4.8% of Inogen shares are owned by insiders. Comparatively, 1.5% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Inogen and Avanos Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$361.94 million3.10$20.95 million$1.0747.07
Avanos Medical$697.60 million3.14$-45,900,000.00$1.0742.76

Inogen has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inogen and Avanos Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inogen-0.66%0.21%0.16%
Avanos Medical1.93%3.20%2.28%

Summary

Avanos Medical beats Inogen on 8 of the 13 factors compared between the two stocks.

Eargo (NASDAQ:EAR) and Inogen (NASDAQ:INGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Insider and Institutional Ownership

95.1% of Inogen shares are owned by institutional investors. 4.8% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Eargo and Inogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EargoN/AN/AN/AN/AN/A
Inogen$361.94 million3.10$20.95 million$1.0747.07

Inogen has higher revenue and earnings than Eargo.

Analyst Ratings

This is a summary of current ratings for Eargo and Inogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eargo00403.00
Inogen03102.25

Eargo currently has a consensus price target of $48.00, indicating a potential downside of 17.06%. Inogen has a consensus price target of $63.00, indicating a potential upside of 22.35%. Given Inogen's higher possible upside, analysts clearly believe Inogen is more favorable than Eargo.

Profitability

This table compares Eargo and Inogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EargoN/AN/AN/A
Inogen-0.66%0.21%0.16%

Summary

Inogen beats Eargo on 6 of the 9 factors compared between the two stocks.

Establishment Labs (NASDAQ:ESTA) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Risk & Volatility

Establishment Labs has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Establishment Labs and Inogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$89.57 million17.82$-38,150,000.00($1.86)-36.62
Inogen$361.94 million3.10$20.95 million$1.0747.07

Inogen has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Establishment Labs and Inogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Establishment Labs-46.40%-49.51%-24.21%
Inogen-0.66%0.21%0.16%

Insider & Institutional Ownership

54.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Establishment Labs and Inogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Establishment Labs01402.80
Inogen03102.25

Establishment Labs currently has a consensus target price of $41.40, suggesting a potential downside of 39.22%. Inogen has a consensus target price of $63.00, suggesting a potential upside of 22.35%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Establishment Labs.

Summary

Inogen beats Establishment Labs on 9 of the 14 factors compared between the two stocks.

Sientra (NASDAQ:SIEN) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Sientra and Inogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sientra-123.88%-174.05%-38.97%
Inogen-0.66%0.21%0.16%

Risk and Volatility

Sientra has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sientra and Inogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sientra00603.00
Inogen03102.25

Sientra currently has a consensus target price of $8.20, suggesting a potential upside of 4.73%. Inogen has a consensus target price of $63.00, suggesting a potential upside of 22.35%. Given Inogen's higher possible upside, analysts plainly believe Inogen is more favorable than Sientra.

Earnings and Valuation

This table compares Sientra and Inogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sientra$83.70 million4.73$-106,820,000.00($2.29)-3.42
Inogen$361.94 million3.10$20.95 million$1.0747.07

Inogen has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

71.0% of Sientra shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 2.8% of Sientra shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inogen beats Sientra on 9 of the 14 factors compared between the two stocks.

Invacare (NYSE:IVC) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Invacare and Inogen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.35$-53,330,000.00($1.06)-8.81
Inogen$361.94 million3.10$20.95 million$1.0747.07

Inogen has lower revenue, but higher earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Invacare has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Institutional & Insider Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Invacare and Inogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00203.00
Inogen03102.25

Invacare currently has a consensus price target of $14.00, indicating a potential upside of 51.02%. Inogen has a consensus price target of $63.00, indicating a potential upside of 22.35%. Given Invacare's stronger consensus rating and higher probable upside, equities analysts clearly believe Invacare is more favorable than Inogen.

Profitability

This table compares Invacare and Inogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
Inogen-0.66%0.21%0.16%

Summary

Inogen beats Invacare on 8 of the 14 factors compared between the two stocks.

Inogen (NASDAQ:INGN) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Institutional & Insider Ownership

95.1% of Inogen shares are owned by institutional investors. Comparatively, 70.8% of Lakeland Industries shares are owned by institutional investors. 4.8% of Inogen shares are owned by insiders. Comparatively, 4.9% of Lakeland Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Inogen and Lakeland Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inogen03102.25
Lakeland Industries00303.00

Inogen currently has a consensus target price of $63.00, indicating a potential upside of 22.35%. Lakeland Industries has a consensus target price of $31.3333, indicating a potential downside of 4.33%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Lakeland Industries.

Profitability

This table compares Inogen and Lakeland Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inogen-0.66%0.21%0.16%
Lakeland Industries18.93%28.75%24.67%

Valuation and Earnings

This table compares Inogen and Lakeland Industries' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$361.94 million3.10$20.95 million$1.0747.07
Lakeland Industries$107.81 million2.46$3.28 million$0.4573.56

Inogen has higher revenue and earnings than Lakeland Industries. Inogen is trading at a lower price-to-earnings ratio than Lakeland Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Inogen has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Lakeland Industries has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.


Inogen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Avanos Medical logo
AVNS
Avanos Medical
1.3$45.75-3.5%$2.26 billion$697.60 million157.76
Eargo logo
EAR
Eargo
1.0$57.43-1.3%$2.17 billionN/A0.00Earnings Announcement
Establishment Labs logo
ESTA
Establishment Labs
1.1$68.11-2.5%$1.64 billion$89.57 million-40.30
Sientra logo
SIEN
Sientra
1.2$7.84-1.0%$399.60 million$83.70 million-4.40Decrease in Short Interest
Invacare logo
IVC
Invacare
1.6$9.34-1.6%$326.63 million$927.96 million-7.59Analyst Downgrade
Lakeland Industries logo
LAKE
Lakeland Industries
1.4$33.10-0.3%$266.18 million$107.81 million9.40Decrease in Short Interest
SMTI
Sanara MedTech
0.8$33.98-6.4%$213.87 million$11.77 million-26.34Decrease in Short Interest
Gap Down
Surgalign logo
SRGA
Surgalign
1.8$2.64-1.9%$211.55 million$308.38 million-1.47Decrease in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$2.64-1.9%$211.55 million$308.38 million-1.47Decrease in Short Interest
Conformis logo
CFMS
Conformis
1.3$1.19-10.9%$101.28 million$77.43 million-3.50Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.2$3.05-5.6%$96.32 million$4.87 million-2.42Analyst Report
Gap Down
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$13.75-1.0%$78.76 million$2.32 million-6.88Decrease in Short Interest
Gap Up
POAI
Predictive Oncology
1.3$1.59-0.6%$51.57 million$1.41 million-0.25Gap Down
AHPI
Allied Healthcare Products
0.5$4.94-2.0%$20.21 million$31.89 million0.00Decrease in Short Interest
NAOV
NanoVibronix
0.5$1.19-4.2%$15.27 million$530,000.00-1.98Increase in Short Interest
News Coverage
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.